In a move to transform HIV prevention, the World Health Organisation has released guidelines for countries to follow before they roll out the injectable pre-exposure prophylaxis (PrEP) for those at the risk of contracting HIV. the injectable<\/p>\n\n\n\n
In an interview with Dr. Clemensia Nakabiito, from Makerere University\/Johns Hopkins University Research Collaboration (MUJHU) and one of the researchers that participated in the research exercise the newly approved injectable, gives a significant advance in preventing HIV after being tested in two randomised studies.<\/p>\n\n\n\n
Uganda was involved in the studies and cabotegravir, the injectable pre-exposure prophylaxis (PrEP), has been found to be more effective than the oral PrEP \u2013 with a 79% reduction in the HIV risk.<\/p>\n\n\n\n
In the guidelines, the first two injections are supposed to be administered four weeks apart, followed by administering an injection every after 8 weeks, Dr Nakabiito said.<\/p>\n\n\n\n
Officials from the ministry of Health said that they are now in preparations to make cabotegravir accessible to all those that need it starting in this financial year.<\/p>\n\n\n\n
According to researchers, long-acting cabotegravir is a safe and highly effective HIV prevention tool, expected to accelerate the country\u2019s efforts in the fight against HIV.<\/p>\n\n\n\n
The Director General of the Uganda Aids Commission (UAC), Dr. Nelson Musoba, said to achieve the United Nations HIV\/AIDS prevention goals, Uganda must push for the rapid and equitable access to all effective prevention tools, including long-acting PrEP.<\/p>\n\n\n\n
According to the recently released UNAIDS HIV Global report, 158 people get infected with HIV\/AIDS in Uganda every day posing a risk to global commitments to put an end to the disease.<\/p>\n","protected":false},"excerpt":{"rendered":"
In a move to transform HIV prevention, the World Health Organisation has released guidelines for countries to follow before they roll out the injectable pre-exposure prophylaxis (PrEP) for those at the risk of contracting HIV. the injectable In an interview with Dr. Clemensia Nakabiito, from Makerere University\/Johns Hopkins University Research Collaboration (MUJHU) and one of…<\/p>\n","protected":false},"author":1,"featured_media":4699,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[9],"tags":[753,15],"class_list":["post-4698","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-arvs","tag-uganda"],"yoast_head":"\n